º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Enterprise

Instem expands again with acquisition of US tech firm

The deal to take over d-Wise Technologies comes just three weeks after its last acquisition

IT solutions provider Instem has agreed a deal to take over a US-based clinical trial technology business.

The Staffordshire company, which is a leading provider of IT solutions and services to the global life sciences market, is set to acquire d-Wise Technologies at the end of the month in a deal worth up to $31 million.

Instem's latest acquisition will allow it to grow and develop new and existing software services and broaden its relationships with existing clients.

It comes just weeks after the company - which is based on Stone Business Park - acquired The Edge in £8.5m deal.

Phil Reason, CEO of Instem, said: "We are delighted to have completed this acquisition. Access to a broad array of data is key to aiding and speeding up drug research and development. We believe that the enlarged group is now even closer to becoming a one-stop-shop for life science companies looking for a long-term relationship as we assist them across the drug discovery and development landscape.

"We have known d-wise for nearly a decade and have been impressed with their growth, as well as the position they have developed as highly trusted thought leaders in clinical trial analysis and regulatory submission technology.

"This is an exciting addition to the group, significantly enhancing our scale and market reach. We very much look forward to building on this as part of our ongoing strategy."

He added: "Our combined capabilities will help us meet the demand by our clients to create a more connected ecosystem across the life sciences in the global effort to bring life enhancing products to market faster.